

**ESTRO Lower GI Course (Rectal/Anal Cancer)
12-14 March 2025 Lisbon, Portugal**

Wednesday 12 March 2025			Speaker
	12.00 – 12.45	Registration	
	12.45 – 13.00	Introduction	E. Fokas
Rectal Cancer			
Session 1: Standard Diagnosis and Treatment (Pivotal clinical trials and current guidelines) MODERATION: K. Haustermans	13.00-14.20	Lecture (15'+5'): New (European) Guidelines: What is considered standard of care for radiotherapy in the surgical setting (TNM-based, MRI-based RT indications, short-course RT, chemoradiation, TNT)?	A. Gilbert
		Lecture (15'+5'): New (European) Guidelines: What is considered standard of care for concurrent and induction/adjuvant chemotherapy?	R. Glynne-Jones
		Lecture (15'+5'): Imaging-based initial local and systemic staging (Role of ERUS, MRI): What are standard procedures, recommended in guidelines?	R. Beets-Tan
		Lecture (15'+5'): Surgical concepts after neoadjuvant treatment (sphincter preservation, LE, surgical complications, TME quality)	G. Beets
	14.20 - 14.30	Break	
MODERATION: C. Rödel/E. Fokas	14.30-16.00	Tumor board: Case presentations (by participants) and questions on standard of care treatment (<u>without</u> organ preservation): Bring your own cases and discuss with experts and other participants	Participants/All teachers
	16.00-16.30	Break	
Session 2: RT dose-response, normal tissue effects, and toxicity MODERATION : C. Rödel	16.30 – 17.40	Lecture (35'+5'): Dose-response, dose-volume effects and dose constraints	A. Appelt
		Lecture (25'+5): Clinical data on acute and late toxicity, supportive treatment during RT/CRT	MA Gambacorta

Thursday 13 March 2025			Speaker
Session 3: RT-delineation MODERATION : K. Haustermans/ A. Appelt MA Gambacorta	9.00 – 10.30	Teaching (30'): International consensus guideline on CTV delineation (panel)	K. Haustermans
		Exercise (30'): Discussion of FALCON contouring of participants: early stage case	A. Gilbert
		Exercise (30'): Discussion of FALCON contouring of participants: advanced stage case	MA Gambacorta
	10.30 – 11.00	Break	
Session 4: Organ Preservation MODERATION : R. Glynne-Jones	11.00 – 12.30	Lecture (15'+5): Organ preservation: Patient selection/surveillance/salvage: View of surgeon	B. Grotenhuis
		Lecture (15'+5): RT-related aspects: Target volumes/dose/fractionation/combination with chemo/role of brachytherapy	K. Haustermans
		Lecture (20'+5) Role of Imaging: Re-staging/monitoring during/after neoadjuvant/definitive treatment	R. Beets-Tan
		(20'+5): New (European) Guidelines: What is considered standard of care for radiotherapy in the organ preservation setting (TNM-based, MRI-based RT indications, short-course RT, chemoradiation, TNT, brachytherapy)?	C. Rödel
	12.30 – 13.30	Lunch	
MODERATION: A. Gilbert/ R. Glynne-Jones	13.30-14.30	Tumor board: Case presentations (by participants) and questions on organ preservation: Bring your own cases and discuss with experts and other participants	Participants/All teachers
Session 5: EXERCISE: IMRT/IGRT and MRI monitoring MODERATION: A. Appelt/R. Beets-Tan	14.30-16.00	Exercise: Group 1: IMRT/VMAT/IGRT/adaptive RT: Pitfalls and challenges (45 min, then swap group)	A. Appelt/A. Gilbert
		Exercise: Group 2: Functional imaging before, during, after RT: How to read MRI (45 min, then swap group)	R. Beets-Tan
	16.00 – 16.30	Break	
Session 6: Quality of life and future perspectives of combined modality treatment for RC MODERATION : MA Gambacorta	16.30 – 17.30	Lecture (15'+5'): Quality of life (QoL)/Patient Reported Outcome Measures (PROMs)	A. Gilbert
		Lecture (15'+5'): Newer chemotherapy, targeted agents and immunotherapy with or without RT	R. Glynne-Jones
		Lecture (15'+5'): Ongoing and planned clinical trials on combined modality treatment for rectal cancer	E. Fokas

Friday 14 March 2025			Speaker
Anal Cancer			
Session 1 Standard Treatment (Pivotal clinical trials and current guidelines) MODERATION: K. Haustermans	9.00-10.00	Lecture (12'+3'): Imaging-based staging and response evaluation/prediction (Role of MRI, PET-CT): What is considered standard?	R. Beets-Tan
		Lecture (12'+3'): Current (European) Guidelines: What is considered standard of care for radiotherapy	A. Gilbert
		Lecture (12'+3'): Current (European) Guidelines: What is considered standard of care for concurrent chemotherapy? Role of induction- and adjuvant chemotherapy?	R. Glynne-Jones
		Lecture (12'+3'): Role of salvage surgery for non-responders, surgery for locoregional recurrent disease	B. Grotenhuis
	10.00-11.00	Tumor board: Case presentations (by participants): Bring your own cases and discuss with experts and other participants	Participants All teachers
	11.00 - 11.30	Break	
Session 2: Group-Exercise Delineation	11.30 – 13.00	Lecture (30'): Atlas and contouring guidelines for anal cancer radiotherapy	MA Gambacorta
		Exercise (60'): Discussion of FALCON contouring of participants: early/advanced stage cases	K. Haustermans/ A. Appelt/ A. Gilbert
	13.00 – 14.00	Lunch	
MODERATION: MA Gambacorta Session 3 RT-techniques and Supportive care	14.00-14.25	Lecture (20'+5'): Treatment planning for anal cancer: state of the art and challenges (IMRT/SIB/adaptive RT)	A. Appelt
MODERATION : C. Rödel/A. Gilbert Session 4 Tumor biology Session 5 Future perspectives of combined modality treatment for AC	14.25-14.50	Lecture (20'+5): Role of molecular markers (e.g. p16, HPV load, tumor infiltrating lymphocytes). Role of targeted agents?	E. Fokas
	14.50-15.40	Lecture (15'+5'): Ongoing and planned clinical trials	K. Haustermans
		Lecture (15'+5'): Clinical endpoints in anal cancer trials	R. Glynne-Jones
		Discussion (20'): Most important research topics and clinical trials. Take home messages	C. Rödel